Method Development for Laser-Diffraction Particle-Size Analysis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Method Development for Laser-Diffraction Particle-Size Analysis
The author examines the process of method development, with reference to ISO 13320:2009 and relevant monographs from the United States and European pharmacopoeias.


Pharmaceutical Technology
pp. 100-106

References

1. ISO 13320:2009 Particle Size Analysis—Laser Diffraction Methods. Part 1: General Principles (2009).

2. USP30–NF25 General Chapter <429>, "Light Diffraction Measurement of Particle Size," pp. 1235–1241.

3. ISO 14488:2007 Particulate materials—Sampling and sample splitting for the determination of particulate properties.

4. Application note MRK373: The Use of Zeta Potential Measurements for Improving Dispersion During Particle Size Measurements, http://www.malvern.com/appnote_particle_size_determination, accessed Sept. 18, 2010.

5. ISO 14887:2000 Sample Preparation—Dispersing procedures for powders in liquids (2000).

6. Ph.Eur. 6.6 General Chapter 2.9.31, "Laser Diffraction Measurement of Particle Size," (EDQM, Strasbourg, France) p. 5103.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here